Effect of long-term treatment with urocortin on the activity of somatic angiotensin-converting enzyme in spontaneously hypertensive rats

Canadian Journal of Physiology and Pharmacology

Volumn 88, Issue 2, 2010, Pages 168-176

  Yang, Cui ^a   Liu, Xiuxia ^b   Li, Shengnan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

Angiotensin (1 7); Angiotensin converting enzyme; Angiotensin converting enzyme inhibitors; Blood pressure; Chymase; Corticotropin releasing factor; Spontaneously hypertensive rats; Urocortin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANGIOTENSIN II; ASTRESSIN; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; NITRIC OXIDE; UROCORTIN I; UROCORTIN III;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ENZYME ACTIVATION; HYPERTENSION; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; TIME FACTORS; UROCORTINS; VASODILATOR AGENTS;

EID: 77649173573     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y09-119     Document Type: Conference Paper

References (43)

1. Akasu, M., Urata, H., Kinoshita, A., Sasaguri, M., Ideishi, M., and Arakawa, K. 1998. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension, 32(3): 514-520. PMID:9740619.
2. Asmar, R.G., Pannier, B., Santoni, J.P., Laurent, S., London, G.M., Levy, B.I., and Safar, M.E. 1988. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation, 78(4): 941-950. PMID:2971473.
3. Basso, N., Paglia, N., Stella, I., de Cavanagh, E.M., Ferder, L., del Rosario Lores Arnaiz, M., and Inserra, F. 2005. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul. Pept. 128(3): 247-252. doi:10.1016/j.regpep.2004.12.027. PMID:15837534.
4. Berecek, K.H., King, S.J., and Wu, J.N. 1993. Angiotensin-converting enzyme and converting enzyme inhibitors. In Cellular and molecular biology of the renin-angiotensin system. Edited by M.K. Raizada, M.I. Phillips, and C. Sumners. CRC Press, Boca Raton, Florida. pp. 183-220.
5. Berk, B.C., Vekshtein, V., Gordon, H.M., and Tsuda, T. 1989. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension, 13(4): 305-314. PMID:2466788.
6. Caldwell, P.R., Seegal, B.C., Hsu, K.C., Das, M., and Soffer, R.L. 1976. Angiotensin-converting enzyme: vascular endothelial localization. Science, 191(4231): 1050-1051. doi:10.1126/science.175444. PMID:175444.
7. Campbell, D.J., Duncan, A.M., Kladis, A., and Harrap, S.B. 1995. Angiotensin peptides in spontaneously hypertensive and normotensive Donryu rats. Hypertension, 25(5): 928-934. PMID:7737729.
8. Carey, R.M., and Siragy, H.M. 2003. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev. 24(3): 261-271. doi:10.1210/er.2003-0001. PMID:12788798.
9. Chen, Z.W., Huang, Y., Yang, Q., Li, X., Wei, W., and He, G.W. 2005. Urocortin-induced relaxation in the human internal mammary artery. Cardiovasc. Res. 65(4): 913-920. doi:10.1016/j. cardiores.2004.11.018. PMID:15721872.
10. Corvol, P., Michaud, A., Soubrier, F., and Williams, T.A. 1995. Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. J. Hypertens. Suppl. 13(supplement 3 3): S3-S10. doi:10.1097/00004872-199509003-00002.
11. Costerousse, O., Allegrini, J., Clozel, J.P., Ménard, J., and Alhenc-Gelas, F. 1998. Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. J. Pharmacol. Exp. Ther. 284(3): 1180-1187. PMID:9495881.
12. Dell'Italia, L.J., and Husain, A. 2002. Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr. Opin. Cardiol. 17(4): 374-379. doi:10.1097/00001573-200207000-00009. PMID:12151872.
13. Ferrario, C.M., Chappell, M.C., Tallant, E.A., Brosnihan, K.B., and Diz, D.I. 1997. Counterregulatory actions of angiotensin-(1-7). Hypertension, 30(3 Pt 2): 535-541. PMID:9322978.
14. Fyhrquist, F., Forslund, T., Tikkanen, I., and Grönhagen-Riska, C. 1980. Induction of angiotensin I-converting enzyme rat lung with Captopril (SQ 14225). Eur. J. Pharmacol. 67(4): 473-475. doi:10.1016/0014-2999(80) 90189-2. PMID:6256177.
15. Gallagher, P.E., Li, P., Lenhart, J.R., Chappell, M.C., and Brosnihan, K.B. 1999. Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension, 33(1 Pt 2): 323-328. PMID:9931124.
16. Gibbons, G.H. 1998. The pathophysiology of hypertension: the importance of angiotensin II in cardiovascular remodeling. Am. J. Hypertens. 11(11 Pt 2): 177S-181S. doi:10.1016/S0895-7061(98)00198-8. PMID:9833876.
17. Groff, J.L., Harp, J.B., and DiGirolamo, M. 1993. Simplified enzymatic assay of angiotensin-converting enzyme in serum. Clin. Chem. 39(3): 400-404. PMID:8383586.
18. + channels. Br. J. Pharmacol. 135(6): 1467-1476. doi:10.1038/sj.bjp.0704587. PMID:11906960.
19. + channels in endothelium-independent relaxation by urocortin in the rat coronary artery. Cardiovasc. Res. 57(3): 824-833. doi:10.1016/S0008-6363(02)00773-3. PMID:12618244.
20. Huang, Y., Yao, X.Q., Lau, C.W., Chan, Y.C., Tsang, S.Y., and Chan, F.L. 2004. Urocortin and cardiovascular protection. Acta Pharmacol. Sin. 25(3): 257-265. PMID:15000874.
21. Kasper, S.O., Basso, N., Kurnjek, M.L., Paglia, N., Ferrario, C.M., Ferder, L.F., and Diz, D.I. 2005. Divergent regulation of circulating and intrarenal renin-angiotensin systems in response to long-term blockade. Am. J. Nephrol. 25(4): 335-341. doi:10.1159/000086571. PMID:15976496.
22. King, S.J., and Oparil, S. 1992. Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cells. Am. J. Physiol. 263(4 Pt 1): C743-C749. PMID:1329541.
23. Krishnaswamy, G., Kelley, J., Johnson, D., Youngberg, G., Stone, W., Huang, S.K., et al. 2001. The human mast cell: functions in physiology and disease. Front. Biosci. 6(1): D1109-D1127. doi:10.2741/krishnas. PMID:11532608.
24. Lai, F.M., Tanikella, T., Herzlinger, H., and Cervoni, P. 1980. Ef-fect of the time interval between blood sampling and assay on serum angiotensin I-converting enzyme activity from captopriltreated rats. Eur. J. Pharmacol. 67(1): 97-99. doi:10.1016/0014-2999(80)90013-8. PMID:6252028.
25. Lau, C.W., Chan, Y.C., Yao, X., Chan, F.L., Chen, Z.Y., and Huang, Y. 2004. Nickel inhibits urocortin-induced relaxation in the rat pulmonary artery. Eur. J. Pharmacol. 488(1-3): 169-172. doi:10.1016/j.ejphar.2004.01.024. PMID:15044048.
26. Liu, C.N., Yang, C., Liu, X.Y., and Li, S. 2005. In vivo protective effects of urocortin on ischemia/reperfusion injury in rat heart via free radical mechanisms. Can. J. Physiol. Pharmacol. 83(6): 459-465. doi:10.1139/y05-033.
27. Miyazaki, M., and Takai, S. 2001. Local angiotensin II-generating system in vascular tissues: the roles of chymase. Hypertens. Res. 24(3): 189-193. doi:10.1291/hypres.24.189. PMID:11409639.
28. Moesgaard, S.G., Pedersen, L.G., Teerlink, T., Häggström, J., and Pedersen, H.D. 2005. Neurohormonal and circulatory effects of short-term treatment with enalapril and quinapril in dogs with asymptomatic mitral regurgitation. J. Vet. Intern. Med. 19(5): 712-719. doi:10.1892/0891- 6640(2005)19[712:NACEOS]2.0.CO;2. PMID:16231716.
29. Oki, Y., and Sasano, H. 2004. Localization and physiological roles of urocortin. Peptides, 25(10): 1745-1749. doi:10.1016/j. peptides.2004.06.023. PMID:15476941.
30. Parkes, D.G., and May, C.N. 2000. Urocortin: a novel player in cardiac control. News Physiol. Sci. 15: 264-268. PMID:11390923.
31. Prasad, A., Husain, S., and Quyyumi, A.A. 1999. Effect of enalaprilat on nitric oxide activity in coronary artery disease. Am. J. Cardiol. 84(1): 1-6. doi:10.1016/S0002-9149(99)00182-4. PMID:10404842.
32. Rademaker, M.T., Charles, C.J., Espiner, E.A., Fisher, S., Frampton, C.M., Kirkpatrick, C.M., et al. 2002. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J. Am. Coll. Cardiol. 40(8): 1495-1505. doi:10.1016/S0735- 1097(02)02170-8. PMID:12392842.
33. Rademaker, M.T., Charles, C.J., Espiner, E.A., Frampton, C.M., Lainchbury, J.G., and Richards, A.M. 2005. Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure. Eur. Heart J. 26(19): 2046-2054. doi:10.1093/eurheartj/ehi227. PMID:15821006.
34. Rotmensch, H.H., Vlasses, P.H., and Ferguson, R.K. 1982. Inhibition of angiotensin-converting enzyme: therapeutic implications. Isr. J. Med. Sci. 18(10): 981-985. PMID:6293997.
35. Santos, R.A., Frézard, F., and Ferreira, A.J. 2005. Angiotensin-(1-7): blood, heart, and blood vessels. Curr. Med. Chem. Cardiovasc. Hematol. Agents, 3(4): 383-391. doi:10.2174/156801605774322373. PMID:16250869.
36. Schweisfurth, H., Kment, A., Dahlheim, H., and Strauer, B.E. 1982. Elevated angiotensin-I-converting enzyme (ACE) in patients with essential hypertension. Klin. Wochenschr. 60(1): 49-50. doi:10.1007/BF01721587. PMID:6281514.
37. Simões E Silva, A.C., Diniz, J.S., Regueira Filho, A., and Santos, R.A. 2004. The renin angiotensin system in childhood hypertension: selective increase of angiotensin-(1-7) in essential hypertension. J. Pediatr. 145(1): 93-98. doi:10.1016/j.jpeds.2004.03.055. PMID:15238914.
38. Singh, L.K., Boucher, W., Pang, X., Letourneau, R., Seretakis, D., Green, M., and Theoharides, T.C. 1999. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin- releasing hormone receptors. J. Pharmacol. Exp. Ther. 288(3): 1349-1356. PMID:10027877.
39. Stanziola, L., Greene, L.J., and Santos, R.A. 1999. Effect of chronic angiotensin converting enzyme inhibition on angiotensin I and bradykinin metabolism in rats. Am. J. Hypertens. 12(10 Pt 1): 1021-1029. doi:10.1016/S0895-7061(99)00090-4. PMID:10560789.
40. Urata, H., Healy, B., Stewart, R.W., Bumpus, F.M., and Husain, A. 1990a. Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. 66(4): 883-890. PMID:2156635.
41. Urata, H., Kinoshita, A., Misono, K.S., Bumpus, F.M., and Husain, A. 1990b. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 265(36): 22348-22357. PMID:2266130.
42. Vaughan, J., Donaldson, C., Bittencourt, J., Perrin, M.H., Lewis, K., Sutton, S., et al. 1995. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature, 378(6554): 287-292. doi:10.1038/378287a0. PMID:7477349.
43. Yang, C., Xu, Y., Mendez, T., Wang, F., Yang, Q., and Li, S. 2006. Effects of intravenous urocortin on angiotensin-converting enzyme in rats. Vascul. Pharmacol. 44(4): 238-246. PMID:16488667.